Feature | August 20, 2012

Baylor Heart Hospital First in the World to Merge Two High-Tech Systems for AFib Therapy

Merging to result in reduced procedure time and higher likelihood of favorable outcome

August 20, 2012 — The Baylor Heart Hospital in Plano, Texas, recently became the first hospital in the world to merge two highly advanced technologies for atrial fibrillation (AF) therapy.

The procedure combined the use of multi-electrode mapping (MEM) software with the Epoch platform, making the full-service cardiovascular hospital the first in the world to do so. Introduced by Biosense Webster, the software allows the physician maneuvering a MEM-enabled catheter to acquire multiple mapping points simultaneously with a higher level of detail. The Epoch platform is an advanced computer-controlled technology that allows physicians to navigate within the patient's heart with robotic precision.

Merging these two technologies means higher levels of efficiencies in mapping and correcting the patient’s cardiac arrhythmias. J. Brian DeVille, M.D., FACC, FHRS, medical director of electrophysiology and an electrophysiologist on the medical staff of the Baylor Heart Hospital, said this first-in-the-world procedure is an important step to further advancing patient care in the arena of cardiac electrophysiology.

“The integration of these two technologies confirms the Heart Hospital Baylor Plano’s commitment to excellence in patient care and providing advanced treatment to our patients,” DeVille said. “Our goal is always to seek ways to further minimize risk to the patient, which then increases the probability of favorable outcomes.”

Mark Valentine, the hospital’s president, added, “The Heart Hospital is fully committed to improving patient outcomes and that involves implementing advanced technologies that will help us fulfill that goal. We consistently strive to be on the forefront when it comes to innovation because we know that ultimately that is what will serve our patients’ interests in positive ways and help us continue to provide safe, quality, compassionate care.”

For more information: www.thehearthospitalbaylor.com

Related Content

Sponsored Content | Videos | Inventory Management| September 21, 2016
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient
Medtronic, CRT, cardiac resynchroniazation therapy devices, heart failure, medication adherence, retrospective analysis, HFSA 2016
News | Heart Failure| September 20, 2016
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure...
don woodlock, GE Healthcare, EP CVIS, electrophyiology
Sponsored Content | Webinar | Cardiac PACS| September 16, 2016
Cardiac rhythm management (CRM) data is becoming increasingly important in the management of patients with implantabl
EBR Systems, FDA, WiSE Technology, Wireless Stimulation Endocardially, SOLVE-CRT study

The WiSE CRT System uses a tiny implant in the left ventricle to synchronize the heart, overcoming limitations of traditional cardiac resynchronization therapy (CRT) in heart failure patients. Graphic courtesy of Business Wire.

News | Cardiac Resynchronization Therapy Devices (CRT)| September 15, 2016
EBR Systems Inc. announced the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption...
Sponsored Content | Videos | Heart Failure| September 02, 2016
The Respicardia Remede System is a pacemaker-like implantable device designed to improve cardiovascular health by res
Respicardia, Remede, pacemaker for sleep apnea, central sleep apnea treatment

The Respicardia Remede System is a pacemaker-like implantable device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with central sleep apnea.

News | Heart Failure| September 02, 2016
September 2, 2016 — Results from an international, randomized study show that an implanted nerve stimulator significa
Pradaxa, dabigatran, GLORIA-AF registry, ESC Congress 2016, NVAF
News | Antiplatelet and Anticoagulation Therapies| September 01, 2016
First outcome results from the GLORIA-AF Registry show that treatment with Pradaxa (dabigatran etexilate mesylate) was...
News | Cardiac Resynchronization Therapy Devices (CRT)| August 30, 2016
August 30, 2016 — Medtronic plc announced results from the...
Medtronic, Micra TPS pacemaker, transcatheter pacing system, global clinical trial, one-year results, ESC 2016
News | Pacemakers| August 29, 2016
August 29, 2016 — Medtronic plc announced new long-term results from the Medtronic Micra Transcatheter Pacing System
Overlay Init